Stephen Hanauer to Cost-Benefit Analysis
This is a "connection" page, showing publications Stephen Hanauer has written about Cost-Benefit Analysis.
Connection Strength
0.301
-
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
Score: 0.161
-
Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48.
Score: 0.069
-
Outsourcing clinical trials. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):191.
Score: 0.068
-
Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med. 1988 Feb; 108(2):274-8.
Score: 0.004